Status:
RECRUITING
Physical Exercise During Preoperative Chemotherapy for Breast Cancer
Lead Sponsor:
Karolinska Institutet
Conditions:
Breast Cancer
Eligibility:
All Genders
18-100 years
Phase:
NA
Brief Summary
Neoadjuvant chemotherapy (NACT) is increasingly used in breast cancer. The best proof of NACT efficacy is pathological complete response (pCR), i.e. the absence of invasive tumour on post-NACT surgica...
Detailed Description
The Neo-ACT assesses the primary endpoint pathological complete response (pCR) and the secondary endpoints Residual Cancer Burden (RCB), objective tumour response (RECIST), all-cause, breast cancer-sp...
Eligibility Criteria
Inclusion
- Patients with primary invasive breast cancer cT1-T3 cN0-2
- Full tumour biology available before initiation of NACT
- Oral and written consent
- Age ≥ 18 years
Exclusion
- Pregnancy or breast-feeding
- Bilateral invasive breast cancer
- The presence of musculoskeletal, neurological, respiratory, metabolic or cardiovascular conditions that may prevent safe completion of the exercise demands of the study
- Currently performing equal to or more than 150 mins of moderate to high intensity aerobic exercise and 2 sessions per week of moderate intensity resistance exercise
Key Trial Info
Start Date :
November 9 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2028
Estimated Enrollment :
712 Patients enrolled
Trial Details
Trial ID
NCT05184582
Start Date
November 9 2022
End Date
June 1 2028
Last Update
September 22 2025
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Cabrini Health
Melbourne, Australia
2
Helsinki University Hospital
Helsinki, Finland
3
Turku University Hospital
Turku, Finland
4
Karolinska University Hospital
Stockholm, Stockholm County, Sweden, 17176